Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of BGT226, Administered Orally in Adult Patients With Advanced Solid Tumor in Japan

NCT00742105 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT00742105
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00742105 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of BGT226, Administered Orally in Adult Patients With Advanced Solid Tumor in Japan
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 1
Overall status
Terminated
Start date
November 17, 2008
Completion date
December 22, 2009
Enrollment
18 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, cancer, solid tumor